Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
vTv Therapeutics
Biotech
China biotech inks $135M deal for remaining rights to vTv med
Having secured regional rights to vTv’s inflammation drug, Newsoara is fronting $20 million to take ownership of the clinical-stage asset globally.
James Waldron
Feb 2, 2026 10:10am
FDA puts vTv's diabetes drug on hold over chromatographic signal
Jul 29, 2024 4:47am
New federal biotech commission taps 12 members—Chutes & Ladders
Feb 3, 2023 10:20am
Amgen vet to be CMO at Affini-T—Chutes & Ladders
Jul 29, 2022 9:30am
vTv CEO resigns four months in and board member takes over
Mar 4, 2022 9:50am
Athira CEO resigns after investigation—Chutes & Ladders
Oct 22, 2021 9:30am
